Skip to main content
. Author manuscript; available in PMC: 2024 Sep 4.
Published in final edited form as: Cancer Immunol Res. 2024 Mar 4;12(3):350–362. doi: 10.1158/2326-6066.CIR-23-0496

Fig. 1∣. LILRB3 expression is associated with reduced survival in patients diagnosed with solid tumors.

Fig. 1∣

(a) Kaplan-Meier survival analysis of correlations between LILRB3 and overall survival of patients from the TCGA database. Patients were stratified with low levels of LILRB3 (blue) or high levels of LILRB3 (red) from TCGA subsets of pan-cancer, renal clear cell carcinoma (KIRC), glioblastoma (GBM), low-grade glioma (LGG), thymoma (THYM), and lung squamous cell carcinoma (LUSC). Statistical significance for overall survival was calculated by Mann-Whitney’s log-rank test. (b) Expression of LILRB3 on the cell surface of different subsets of lymphocytes, monocytes, and granulocytes in a representative human patient with melanoma by flow cytometry.